NEOK Bio

Emerging

NEOK Bio emerged from stealth in 2025 with $80M in funding targeting neuroinflammation pathways in Alzheimer's disease and ALS using a novel class of innate immune modulators.

Company Overview

About NEOK Bio

NEOK Bio is targeting neuroinflammation — the chronic activation of brain immune cells (microglia and astrocytes) — as a primary driver of neurodegeneration in Alzheimer's disease, ALS, and Parkinson's disease. The company's small molecule drug candidates modulate the NLRP3 inflammasome and related innate immune pathways in the brain, aiming to reduce the toxic inflammatory environment that kills neurons over time.

Business Model & Competitive Advantage

Founded in 2022 and emerging from stealth in 2025, NEOK Bio's scientific foundation draws from decade-long academic research linking neuroinflammation biomarkers to disease progression rates. The $80M funding will advance lead candidates into IND-enabling studies targeting a 2026 clinical trial initiation for its ALS program.

Competitive Landscape 2025–2026

Neuroinflammation as a therapeutic target has gained significant traction following the partial success of anti-amyloid antibodies (Leqembi, Kisunla) in Alzheimer's — which work partly by reducing inflammatory burden — and the identification of microglial genetic variants (TREM2, CD33) as major Alzheimer's risk factors. NEOK Bio's approach complements amyloid-targeting strategies by addressing the inflammatory component of neurodegeneration.

Revenue
$80M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

NEOK Bio is an emerging player bringing innovative solutions to the BioTech market.

Frequently Asked Questions

Not So Random Others

a2z Radiology AI

Enterprise AI
Ai PoweredB2bEnterpriseHealthtechSaasStartup

a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea

Adept AI

AI Infra
Ai PoweredAutomationB2bEnterpriseInfrastructurePlatformStartupSaas

Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec

Plenty

AgTech & Precision Agriculture Technology
AgricultureAi PoweredHardwareIotPlatformSaasScaleupStartupB2b

Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r

80 Acres Farms

AgTech
AgricultureSaasB2bStartup

80 Acres Farms is a commercial-scale indoor vertical farming company that, following its merger with Soli Organic, operates the largest indoor farming network in North America. The company raised $115

Duckie

Infrastructure
Ai PoweredAutomationB2bInfrastructurePlatformCloud NativeSaas

Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit

Honda

Automotive
Asia PacificB2cGlobalHardwareManufacturingPublicTransportation

Honda Motor Co., Ltd. is a Japanese multinational mobility conglomerate founded in 1948 by Soichiro Honda and Takeo Fujisawa in Hamamatsu, Japan. Starting as a motorcycle manufacturer, Honda expanded

Compare NEOK Bio with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For NEOK Bio

Claim This Profile

Are you from NEOK Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim NEOK Bio Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention NEOK Bio vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →